Does RAPP pay a dividend and is it safe?

Rapport Therapeutics Inc. (RAPP) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / RAPP / dividends

SNDX (17) VSTM (36) AMPH (72) SLN (44) ⌘ Pro Terminal →

Rapport Therapeutics Inc. (RAPP) Dividend Safety Gauge & 10-Year DRIP Compounder

$25.13 +0.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $25.10

Rapport Therapeutics Inc. (RAPP) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.20B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RAPP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RAPP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Rapport Therapeutics Inc. (NASDAQ: RAPP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $25.13 (+0.32% 1D, market cap $1.20B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RAPP ranks #788 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RAPP compare to SNDX and VSTM in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RAPP carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.9%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and VSTM (Verastem Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RAPP?

▼

Per RAPP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002012593), Rapport Therapeutics Inc. generated $350.3M in revenue (+50.6% YoY), -$111.5M in net income, and -$88.1M in free cash flow against $512.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $25.10 (-0.13%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RAPP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY RAPP SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$28.99+1.3% Next Q

Q2 (-2Q)

Grade E$29.37-6.2% Next Q

Q3 (-1Q)

Grade E$27.54-8.8% Next Q

Current

Grade E$25.13-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RAPP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RAPP currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($35.74) and Max Pain ($26.39) forces dealer call-delta covering toward $55.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RAPP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RAPP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RAPP)

✓Walkthrough of RAPP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RAPP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.27%📐 HORIZONTAL RANGE

2026-11-03O $24.21H $25.13L $24.21C $25.13VOL 926.6K

RES: $60.43SUP: $21.64SMA50: $35.74SMA200: $35.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RAPP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RAPP Butterfly Map → + Track RAPP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RAPP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RAPP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RAPP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RAPP)

Health Care Rank #788 of 1016 ⚔️ SNDX vs RAPP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RAPP vs. SNDX, VSTM, AMPH, SLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rapport Therapeutics Inc. (RAPP) ranks #788 by composite RQD confidence (30/100, grade E) and #334 by equity capitalization ($1.20B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with RAPP at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RAPP ACTIVE Rapport Therapeutics Inc.	E	30/100	—	—	-22.9%	+0.32%	$1.20B	Benchmark Subject
SNDX Syndax Pharmaceuticals Inc.	E	17/100	—	—	-35.0%	-4.03%	$1.22B	/sndx-vs-rapp →
VSTM Verastem Inc.	D-	36/100	—	—	-35.0%	-1.64%	$1.18B	/vstm-vs-rapp →
AMPH Amphastar Pharmaceuticals Inc.	B	72/100	11.7x	49.5%	9.0%	-2.49%	$1.18B	/amph-vs-rapp →
SLN Silence Therapeutics Plc American Depository Share	D	44/100	—	61.5%	-35.0%	+0.05%	$1.23B	/sln-vs-rapp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002012593

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rapport Therapeutics Inc. (RAPP) reported GAAP revenue of $350.3M (+50.6% vs. FY2024 revenue of $232.6M , and +245.8% cumulative change since FY2023) , GAAP net income of -$111.5M, operating cash flow of -$87.5M, and free cash flow of -$88.1M (-31.0% YoY). On the balance sheet, RAPP closed FY2025 with $512.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$350.3M	-$111.5M	-$87.5M	-$88.1M	$512.4M	—
FY2024 (FY)	2024-12-31	$232.6M	-$78.3M	-$64.8M	-$67.2M	$314.9M	—
FY2023 (FY)	2023-12-31	$101.3M	-$34.8M	-$27.2M	-$27.2M	—	—

3. RAPP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RAPP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RAPP compare to SNDX and VSTM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RAPP?

Where is RAPP trading relative to its 50-day, 200-day, and 52-week technical levels?

RAPP last traded at $25.13 (+0.32% on volume of 1,327,819 shares), positioning the stock -29.69% below its 50-day simple moving average ($35.74) and -29.47% below its 200-day simple moving average ($35.63). Across its 52-week range of $22.06 to $52.93, RAPP sits at the 9.9% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($21.99 to $28.27).

Direct Sub-Reports: RAPP RQD Cockpit RAPP 12M Forecast RAPP Earnings & Move RAPP Dividends & DRIP RAPP Insiders & 13F RAPP Whale Options RAPP Profit Sankey RAPP News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RAPP — Rapport Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:30:27Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

RAPP carries an RQD score of 31 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars score as follows:

Fundamental cash engine: 7 / 20. The rating cites ROIC of -22.9% and an FCF yield of -7.58%. For a prospective investor, this means the business is consuming cash rather than generating it, so any valuation rests on future outcomes not yet visible in reported results.
Whale / 13F flow: 5 / 20. The rating reflects institutional accumulation and options positioning, which is weak here. Institutional conviction is a supportive signal for many stocks; its absence removes one common source of upside confirmation.
Insider conviction: 3 / 20. The rating cites an SEC Form 4 and congressional PTR cluster flow. This is the lowest pillar and indicates limited insider-side support for the equity.
Macro regime fit: 6 / 20. The rating shows a beta of 1.0 and sector sensitivity. The stock moves in line with the broader market, offering no defensive cushion or macro tailwind identified in the source data.
Forensic balance sheet: 10 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. The Piotroski score is weak, which signals deteriorating fundamentals across multiple tests, while the Z-Score sits in a range that warrants monitoring rather than signaling immediate distress.

Taken together, the rating frames RAPP as a name where upside would depend on catalysts outweighing a cash-burning income statement and weak forensic and ownership signals.

2. Business Model, Unit Margins & SEC Financial Trajectory

Rapport Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The profile states a market capitalization of $1.2B.

Operating losses widened from -$36.2M in FY 2023 to -$125.1M in FY 2025, and free cash flow outflow widened from -$27.2M to -$88.1M over the same span. Gross, operating, and net margins are each reported as 0% in the market data, consistent with no reported revenue. The Roarable RQD rating cites ROIC of -22.9%, an Altman Z-Score of 2.5, and a Piotroski F-Score of 2/9. Cash declined from $56.8M in FY 2024 to $52.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: The stock trades at $24.21 after a 7.6% gain, roughly 54% above its $22.06 52-week low, with a $1.16B market cap relative to a $52.6M cash balance. With Fundamental Cash Engine at 7/20 (ROIC -22.9%, FCF yield -7.58%) and Institutional Whale Flow at 4/20, sustained execution supports upside toward the top of the $22.06 – $52.93 52-week range.
🐻 Primary Bear Case: Operating losses widened from -$36.2M in FY 2023 to -$125.1M in FY 2025 while the Roarable RQD rating scores the company 31 with a Piotroski F-Score of 2/9. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only cross-company reference in the news wire is the AbbVie market mention, which is a headline reference and does not establish a supply-chain link in the source data.

Key Question #1: What is the company's cash runway given $52.6M of cash against an FY 2025 free cash outflow of -$88.1M?
Key Question #2: What is the debt position, which is reported as N/A across the financial periods?
Key Question #3: What drove the 29% monthly slide and the 20% after-hours decline referenced in the news wire?

RAPP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rapport Therapeutics Inc. (RAPP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RAPP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

Rapport Therapeutics (RAPP) Stock Seems Pricey Following A 29% Monthly Slide

Yahoo Finance report covering Rapport Therapeutics Inc. (RAPP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 23h ago

RAPP Stock Price and Chart — NASDAQ:RAPP

TradingView report covering Rapport Therapeutics Inc. (RAPP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investor's Business Daily • 1d ago

Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Rises

Investor's Business Daily report covering Rapport Therapeutics Inc. (RAPP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Rapport Therapeutics, Inc. (RAPP) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Rapport Therapeutics Inc. (RAPP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock

Investing.com report covering Rapport Therapeutics Inc. (RAPP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Benzinga • 1d ago

Rapport Therapeutics (RAPP) Shares Sink 20% After Hours

Benzinga report covering Rapport Therapeutics Inc. (RAPP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Rapport Therapeutics stock tumbles on $350M capital raise

Investing.com report covering Rapport Therapeutics Inc. (RAPP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Rapport Therapeutics (RAPP) Stock Gets Fair Value Boost After RAP 219 Bipolar Mania Data

Yahoo Finance report covering Rapport Therapeutics Inc. (RAPP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RAPP Bull vs. Bear Conversation Board — What's Your Call at $25.13?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RAPP 🐻 33% BEARISH CONVICTION

BR BreakoutHunter Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $32.56 (+30.0%)

📌 Pinned Debate

The stock trades at $24.21 after a 7.6% gain, roughly 54% above its $22.06 52-week low, with a $1.16B market cap relative to a $52.6M c

Here is why I am bullish on RAPP here at $25.05: The stock trades at $24.21 after a 7.6% gain, roughly 54% above its $22.06 52-week low, with a $1.16B market cap relative to a $52.6M cash balance.. Compare RAPP's 0.0% operating margin and -22.9% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $23.80 are getting bought.

SectorRotator 🐂 BULL

@BreakoutHunter Agree on the RQD 30/100 quality, though with 1.0 beta I'm scaling in with half-size at $25.05 and keeping dry powder in case we test $23.30.

ME MeanReversion_88 Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $19.79 (-21.0%)

Spot @ $25.05

Operating losses widened from -$36.2M in FY 2023 to -$125.1M in FY 2025 while the Roarable RQD rating scores the company 31 with a Piot

Operating losses widened from -$36.2M in FY 2023 to -$125.1M in FY 2025 while the Roarable RQD rating scores the company 31 with a Piotroski F-Score of 2/9.. Look at the math on RAPP: paying current EV/EBITDA multiples for -22.9% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $22.04 before getting long.